Literature DB >> 16168650

Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity.

Jun F Liang1, Victor C Yang.   

Abstract

Cell penetrating peptide TAT was introduced into doxorubicin structure. Synthesized doxorubicin-TAT conjugate showed different intracellular distribution pattern and cell killing activity from those of free doxorubicin. Unlike free doxorubicin, doxorubicin-TAT conjugate was highly permeable to drug-resistant cells and was able to kill drug-resistant tumor cells efficiently.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16168650     DOI： 10.1016/j.bmcl.2005.07.087

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  27 in total

1.  Design of a disulfide-less, pharmacologically inert, and chemically competent analog of maurocalcine for the efficient transport of impermeant compounds into cells.

Authors:  Narendra Ram; Norbert Weiss; Isabelle Texier-Nogues; Sonia Aroui; Nicolas Andreotti; Fabienne Pirollet; Michel Ronjat; Jean-Marc Sabatier; Hervé Darbon; Vincent Jacquemond; Michel De Waard
Journal:  J Biol Chem       Date:  2008-07-11       Impact factor: 5.157

2.  Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide.

Authors:  Gu Xiao; George K Annor; Kimberly Fung; Outi Keinänen; Brian M Zeglis; Jill Bargonetti
Journal:  Mol Pharm       Date:  2020-12-08       Impact factor: 4.939

3.  Targeted delivery of doxorubicin through conjugation with EGF receptor-binding peptide overcomes drug resistance in human colon cancer cells.

Authors:  Shibin Ai; Tao Jia; Weilun Ai; Jianli Duan; Yongmei Liu; Jing Chen; Xin Liu; Fan Yang; Yuan Tian; Zebo Huang
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

4.  Anthracycline Nano-Delivery Systems to Overcome Multiple Drug Resistance: A Comprehensive Review.

Authors:  Ping Ma; Russell J Mumper
Journal:  Nano Today       Date:  2013-06-01       Impact factor: 20.722

5.  Synthesis of a covalent epirubicin-(C(3)-amide)-anti-HER2/neu immunochemotherapeutic utilizing a UV-photoactivated anthracycline intermediate.

Authors:  Cody P Coyne; Toni Jones; Ryan Bear
Journal:  Cancer Biother Radiopharm       Date:  2011-12-22       Impact factor: 3.099

6.  The pH sensitivity of histidine-containing lytic peptides.

Authors:  Zhigang Tu; Albert Young; Christopher Murphy; Jun F Liang
Journal:  J Pept Sci       Date:  2009-11       Impact factor: 1.905

7.  Maurocalcine as a non toxic drug carrier overcomes doxorubicin resistance in the cancer cell line MDA-MB 231.

Authors:  Sonia Aroui; Narendra Ram; Florence Appaix; Michel Ronjat; Abderraouf Kenani; Fabienne Pirollet; Michel De Waard
Journal:  Pharm Res       Date:  2008-12-13       Impact factor: 4.200

8.  Synthesis of Gemcitabine-(C4-amide)-[anti-HER2/neu] Utilizing a UV-Photoactivated Gemcitabine Intermediate: Cytotoxic Anti-Neoplastic Activity against Chemotherapeutic-Resistant Mammary Adenocarcinoma SKBr-3.

Authors:  Cody P Coyne; Toni Jones; Ryan Bear
Journal:  J Cancer Ther       Date:  2012-10

9.  Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters.

Authors:  Elena A Dubikovskaya; Steve H Thorne; Thomas H Pillow; Christopher H Contag; Paul A Wender
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-19       Impact factor: 11.205

10.  Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models.

Authors:  Anjali Apte; Erez Koren; Alexander Koshkaryev; Vladimir P Torchilin
Journal:  Cancer Biol Ther       Date:  2013-10-21       Impact factor: 4.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.